ondansetron has been researched along with levodopa in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brown, D; Factor, SA; Molho, ES; Podskalny, GD | 1 |
| Friedberg, G; Melamed, E; Weizman, A; Zoldan, J | 1 |
| Brunt, E; Eichhorn, TE; Oertel, WH | 1 |
| Roczniak, W | 1 |
| Babuśka-Roczniak, M; Brodziak-Dopierała, B; Cipora, E; Kwapuliński, J; Nowak, P; Oświęcimska, JM; Roczniak, W; Widuchowski, W | 1 |
| El-Kosasy, AM; Hussein, LA; Mohamed, NM; Salama, NN | 1 |
| Bédard, D; Clarke, PB; Frouni, I; Hamadjida, A; Huot, P; Kwan, C; Lévesque, C; Lévesque, D; Yesuf, JM | 1 |
1 review(s) available for ondansetron and levodopa
| Article | Year |
|---|---|
Parkinson's disease: drug-induced psychiatric states.
Topics: Aged; Anxiety; Bipolar Disorder; Clozapine; Depression; Electroconvulsive Therapy; Humans; Levodopa; Lisuride; Male; Ondansetron; Parkinson Disease; Psychoses, Substance-Induced; Sexual Dysfunctions, Psychological | 1995 |
1 trial(s) available for ondansetron and levodopa
| Article | Year |
|---|---|
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Delusions; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Ondansetron; Parkinson Disease; Serotonin Antagonists | 1996 |
11 other study(ies) available for ondansetron and levodopa
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Ondansetron treatment of L-dopa-induced psychosis.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Ondansetron; Psychoses, Substance-Induced | 1996 |
Assessment of dopamine (DA) synthesis rate in selected parts of the rat brain with central noradrenergic lesion after administration of 5-HT3 receptor ligands.
Topics: Adrenergic Neurons; Animals; Benzylamines; Brain Injuries; Brain Stem; Carboxy-Lyases; Dopamine; Frontal Lobe; Hypothalamus; Levodopa; Male; Morphine; Ondansetron; Rats; Rats, Wistar; Receptors, Serotonin, 5-HT3; Thalamus | 2013 |
The effect of central noradrenergic system lesion on dopamine (DA) and serotonin (5-HT) synthesis rate following administration of 5-HT3 receptor ligands in chosen parts of the rat brain.
Topics: Analgesics, Opioid; Animals; Autonomic Nervous System Diseases; Benzylamines; Biguanides; Brain Chemistry; Cerebellum; Dopamine; Hippocampus; Levodopa; Ligands; Male; Morphine; Neurotoxins; Ondansetron; Rats; Rats, Wistar; Serotonin; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2015 |
New and validated RP-HPLC Method for Quantification of Safinamide Mesylate in Presence of Its Basic Degradate, Levodopa and Ondansetron: Application to Human Plasma.
Topics: Alanine; Benzylamines; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Levodopa; Limit of Detection; Linear Models; Ondansetron; Reproducibility of Results; Tablets | 2020 |
Autoradiographic labelling of 5-HT
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetron; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonin; Subthalamic Nucleus | 2022 |